Sense raises € 4.5 million to improve measurement of blood pressure


The Danish company Sense A/S just raised € 4.5 million for their groundbreaking medical technology for blood pressure measurement. The technology works seamlessly and will remedy incorrect diagnostics of hypertension at the physicians' offices, which themselves can cause elevated readings. The total investment from venture fund SEED Capital and Vækstfonden will be used to refine the product and for commercial launch in 2013.

High blood pressure affects more than ¼ of the Western world population and it is estimated that up to 12% of all deaths can be linked to this disorder. Hypertension is therefore one of the world's largest disease areas and the most important factor in the treatment of this is an accurate diagnosis. Current diagnostic solution of choice is the measurement of blood pressure at the physicians' offices, and typically using the cuff method. However this solution has a number of challenges including discomfort with the measurement itself and nervousness during the consultation which both may contribute to erroneous measurements. In addition, the realization is that a variety of cardiovascular diseases can be diagnosed much better by measuring blood pressure over a standard 24-hour circadian rhythm, and for this the cuff method is not very suitable.

The Danish company Sense A/S develops ContiPress™, which continuously measures the patient's blood pressure 24 hours a day, down to every 10 second day and night, without the user noticing. ContiPress™ consists of an intelligent patch, which the doctor or nurse places on the patient's upper arm. From there, the unit monitors the patient's blood pressure over 24 hours and stores the data for subsequent analysis via an enclosed piece of software. The result is comprehensive data about the patient's blood pressure over 24 hours and thus an optimal basis for making the correct diagnosis.

Sense has raised € 4.5 million in an investment round with venture fund SEED Capital and Vækstfonden. It is the company third round, since it was founded in 2006 in connection with an investment from SEED Capital. Second round of investment came from SEED Capital and Vækstfonden in 2010. ContiPress™ is currently a prototype that has been clinically tested on people with very large differences in both blood pressure, BMI (body mass index) and age with promising results that verify the measurement principle. The investment round will be used to refine the device and try ContiPress™ in a more extensive clinical testing within the expected commercial launch.

More info: 

News archive

  • 2015-08-18

    Acarix receives CE Mark

    The CADScor® System is indicated for use as an acoustic decision support tool for diagnosing patients suspected of Coronary Artery Disease.The CADScor® System was developed to rule out suspected coronary artery disease (CAD) based on the detection of diastolic murmurs from post-stenosis coronary

  • 2015-08-13

    SEED Capital appoints new partner

    Former Investment Director of the tech-team, Niels Vejrup Carlsen, has joined the partner team as of 1st of June 2015.

  • 2015-08-12

    CloudCutout to revolutionise Adobe’s Photoshop

    It is no secret that Google is smitten with machine learning and the endless possibilities of automation.

  • 2015-07-09

    Lisa Dam is our new Investment Manager

    SEED Capital has an increased focus on medical technology as an investment area, as this area represents great potential partly because the way from innovation to market doesn’t necessarily have to be particularly long.

  • 2015-06-22

    Jørgen Lindegaard becomes new Chairman of Pre-Seed Innovation

    Jørgen Lindegaard has a past as CEO of GN Store Nord, SAS and most recently ISS, which he left in 2010 to join a number of boards such as Scandia Denmark, The IT University of Copenhagen and Zealand Pharma. Now he joins the Board of Pre-Seed Innovation.

  • 2015-06-04

    SEED Capital announces establishment of new fund

    First closing has been completed with pledges from among others ATP, Dansk Vækstkapital, The Danish Growth Fund and Augustinus Fonden.

  • 2015-06-02

    AIRTAME Launches Streaming Solution for Enterprises

    Following a record-setting crowdfunding campaign on Indiegogo, AIRTAME has made its high-performance wireless streaming solution for enterprises available for direct purchase.

  • 2015-05-28

    Trustpilot Closes $73,5 Million Series D Round

    Trustpilot, the leading review community for global online shoppers, today announced that it has raised $73,5 million in a Series D investment round, making it one of the largest investments in a venture backed company in Denmark ever.  The round was led by the private equity firm, Vitr

  • 2015-05-13

    Study Shows Effectiveness of Reapplix' LeucoPatch in Healing Diabetic Foot Ulcers

    A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers.

  • 2015-05-06

    Gilead Sciences acquires EpiTherapeutics for $65 million

    Today it has been announced that EpiTherapeutics has been sold to American Gilead Sciences for $65 million equivalent to 444 million kroner.




Where to meet us

Press Kit

SEED Capital Ulla Brockenhuus-Schack

SEED Capital logo
Download as png (8 kb)
Download as eps (374 kb)

Ulla Brockenhuus-Schack
Download as jpg (1.1 mb)

Download our full press kit containing pictures of our employees here

Contact Information
Communications Manager: Line Byrfelt Grønlykke
Phone: +45 4111 2191